Brief: Geneuro: 1st Patient Having Finished Protect-MS Study Has Entered Study Extension

Geneuro SA

22/09/2021 09:45

Sept 22 (Reuters) - Geneuro SA  GNRO.PA :
    * GENEURO ANNOUNCES THAT A FIRST PATIENT HAVING FINISHED THE
PROTECT-MS STUDY AT THE KAROLINSKA INSTITUTET’S ACADEMIC
SPECIALIST CENTER HAS ENTERED THE STUDY EXTENSION
    * RESULTS FROM PROTECT-MS REMAIN ON TRACK FOR Q1 2022
    * STUDY EXTENSION INITIATED TO OFFER PATIENTS OPPORTUNITY TO
CONTINUE RECEIVING TEMELIMAB AFTER COMPLETING ONE-YEAR STUDY
    * EXTENSION STUDY AIMS AT PROVIDING TREATMENT TO ALL
PATIENTS WHO
HAVE COMPLETED THEIR ONE-YEAR TREATMENT DURATION, UNTIL RESULTS
OF CORE PROTECT-MS STUDY ARE AVAILABLE IN SPRING OF 2022

Source text for Eikon:  ID:nBw4xw3Bta 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))